# Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma

> **NCT02010606** · PHASE1 · COMPLETED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 39 (actual)

## Conditions studied

- Glioblastoma
- Glioblastoma Multiforme
- Glioma
- Astrocytoma
- Brain Tumor

## Interventions

- **BIOLOGICAL:** Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy
- **BIOLOGICAL:** Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab

## Key facts

- **NCT ID:** NCT02010606
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-08
- **Primary completion:** 2019-01-23
- **Final completion:** 2021-07-10
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02010606

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02010606, "Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02010606. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*